Biologics & Biosimilars

Biosimilars: How Do They Affect Patient Care & Safety?

March 19, 2019 • By Lara C. Pullen, PhD

WindNight / shutterstock.com

Why & How Our Biologic Drug Discussion with Patients Should Evolve

February 17, 2019 • By Paul H. Caldron, DO, PhD, MBA, & John R.P. Tesser, MD

Biosimilar ABP 798 Promising for RA

February 13, 2019 • By Michele B. Kaufman, PharmD, BCGP

FDA Approves Rituximab Biosimilar; Plus New Safety Data for Filgotinib in RA Patients

January 7, 2019 • By Michele B. Kaufman, PharmD, BCGP

VA Study Tracks Biologics Usage, Finds Dramatic Patient-Age Difference

December 17, 2018 • By Catherine Kolonko

5-Year Data on Secukinumab in AS; Oliceridine Not Recommended for FDA Approval

November 7, 2018 • By Michele B. Kaufman, PharmD, BCGP

Ixekizumab Improves Outcomes of Ankylosing Spondylitis

November 5, 2018 • By Will Boggs, MD

Plaque Psoriasis Treatments: BMS-986165 Promising & Adalimumab Biosimilar Demonstrates Equivalence

October 22, 2018 • By Michele B. Kaufman, PharmD, BCGP

Zilretta Promising for Blood Glucose Levels; Plus Filgotinib Promising for RA

October 15, 2018 • By Michele B. Kaufman, PharmD, BCGP

California Insurance Commissioner Sues AbbVie over Humira

September 23, 2018